A detailed history of Redmile Group, LLC transactions in Immunome Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 4,889,554 shares of IMNM stock, worth $56.7 Million. This represents 3.86% of its overall portfolio holdings.

Number of Shares
4,889,554
Previous 4,889,554 -0.0%
Holding current value
$56.7 Million
Previous $121 Million 50.97%
% of portfolio
3.86%
Previous 4.76%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$11.01 - $27.34 $11.1 Million - $27.6 Million
1,010,139 Added 26.04%
4,889,554 $121 Million
Q4 2023

Feb 14, 2024

BUY
$7.3 - $10.73 $28.3 Million - $41.6 Million
3,879,415 New
3,879,415 $41.5 Million

Others Institutions Holding IMNM

About Immunome Inc.


  • Ticker IMNM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,127,400
  • Market Cap $141M
  • Description
  • Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...
More about IMNM
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.